285 related articles for article (PubMed ID: 24572789)
1. Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer.
Morris JC; Ramlogan-Steel CA; Yu P; Black BA; Mannan P; Allison JP; Waldmann TA; Steel JC
Gene Ther; 2014 Apr; 21(4):393-401. PubMed ID: 24572789
[TBL] [Abstract][Full Text] [Related]
2. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.
Zhang M; Ju W; Yao Z; Yu P; Wei BR; Simpson RM; Waitz R; Fassò M; Allison JP; Waldmann TA
J Immunol; 2012 Jun; 188(12):6156-64. PubMed ID: 22593619
[TBL] [Abstract][Full Text] [Related]
3. IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.
Shi Y; Dincheva-Vogel L; Ayemoba CE; Fung JP; Bergamaschi C; Pavlakis GN; Farzaneh F; Gaensler KML
Blood Adv; 2018 Nov; 2(22):3177-3192. PubMed ID: 30482760
[TBL] [Abstract][Full Text] [Related]
4. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.
Guo S; Smeltz RB; Nanajian A; Heller R
Front Immunol; 2020; 11():614667. PubMed ID: 33628206
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.
Steel JC; Ramlogan CA; Yu P; Sakai Y; Forni G; Waldmann TA; Morris JC
Cancer Res; 2010 Feb; 70(3):1072-81. PubMed ID: 20086176
[TBL] [Abstract][Full Text] [Related]
6. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
Dubois S; Patel HJ; Zhang M; Waldmann TA; Müller JR
J Immunol; 2008 Feb; 180(4):2099-106. PubMed ID: 18250415
[TBL] [Abstract][Full Text] [Related]
7. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
8. Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15Rα.
Sato N; Sabzevari H; Fu S; Ju W; Petrus MN; Bamford RN; Waldmann TA; Tagaya Y
Blood; 2011 Apr; 117(15):4032-40. PubMed ID: 21304101
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans.
Rowley J; Monie A; Hung CF; Wu TC
J Immunol; 2008 Dec; 181(12):8237-47. PubMed ID: 19050240
[TBL] [Abstract][Full Text] [Related]
10. Cell-Based IL-15:IL-15Rα Secreting Vaccine as an Effective Therapy for CT26 Colon Cancer in Mice.
Thi VAD; Jeon HM; Park SM; Lee H; Kim YS
Mol Cells; 2019 Dec; 42(12):869-883. PubMed ID: 31760731
[TBL] [Abstract][Full Text] [Related]
11. NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells.
Robinson TO; Hegde SM; Chang A; Gangadharan A; Rivas S; Madakamutil L; Zalevsky J; Miyazaki T; Schluns KS
J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34375310
[TBL] [Abstract][Full Text] [Related]
12. Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1.
Gaston DC; Odom CI; Li L; Markert JM; Roth JC; Cassady KA; Whitley RJ; Parker JN
PLoS One; 2013; 8(11):e81768. PubMed ID: 24312353
[TBL] [Abstract][Full Text] [Related]
13. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
[TBL] [Abstract][Full Text] [Related]
14. Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives.
Xu H; Shi M; Shao C; Li H; Wu J; Yu Y; Fang F; Guo Y; Xiao W
Microb Cell Fact; 2021 Jun; 20(1):115. PubMed ID: 34107983
[TBL] [Abstract][Full Text] [Related]
15. Adipocytes: A Novel Target for IL-15/IL-15Rα Cancer Gene Therapy.
Xiao R; Mansour AG; Huang W; Chrislip LA; Wilkins RK; Queen NJ; Youssef Y; Mao HC; Caligiuri MA; Cao L
Mol Ther; 2019 May; 27(5):922-932. PubMed ID: 30833178
[TBL] [Abstract][Full Text] [Related]
16. The IL-15 receptor {alpha} chain cytoplasmic domain is critical for normal IL-15Ralpha function but is not required for trans-presentation.
Wu Z; Xue HH; Bernard J; Zeng R; Issakov D; Bollenbacher-Reilley J; Belyakov IM; Oh S; Berzofsky JA; Leonard WJ
Blood; 2008 Dec; 112(12):4411-9. PubMed ID: 18796634
[TBL] [Abstract][Full Text] [Related]
17. IL-15 can signal via IL-15Rα, JNK, and NF-κB to drive RANTES production by myeloid cells.
Chenoweth MJ; Mian MF; Barra NG; Alain T; Sonenberg N; Bramson J; Lichty BD; Richards CD; Ma A; Ashkar AA
J Immunol; 2012 May; 188(9):4149-57. PubMed ID: 22447977
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between IL-15Rα
Zhang W; Zhang Q; Yang N; Shi Q; Su H; Lin T; He Z; Wang W; Guo H; Shen P
Cancer Commun (Lond); 2022 Jun; 42(6):536-557. PubMed ID: 35615815
[TBL] [Abstract][Full Text] [Related]
19. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
[TBL] [Abstract][Full Text] [Related]
20. Configuration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity.
Hong E; Usiskin IM; Bergamaschi C; Hanlon DJ; Edelson RL; Justesen S; Pavlakis GN; Flavell RA; Fahmy TM
J Biol Chem; 2016 Apr; 291(17):8931-50. PubMed ID: 26719339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
